“…Due to the prevalence, high recurrence rate, and potentially fatal nature of cancer, early detection and monitoring of cancer markers is very important for improving oncology patient outcomes 8 . Cancer biomarkers such as CEA 56 , AFP 45 , carbohydrate antigen 125 (CA125) 40 , prostate-specific antigen (PSA) 57 , carbohydrate antigen 72-4 (CA72-4) 58 , the extracellular domain of human epidermal growth factor receptor 2 (HER2-ECD) 59 , cytokeratin fragment antigen 21-1 (CYFRA21-1) 60 and other proteins have been used for the detection, early screening, or prognosis assessment of many cancers, such as colorectal cancer, hepatocellular cancer (HCC), ovarian cancer, prostate cancer (PCa), gastric cancer, breast cancer, and non-small-cell lung cancer. Several electrochemical biosensors for cancer biomarker detection are described below.…”